ArticleExperimental and therapeutic medicine2025
Laser localization with soft‑channel minimally invasive surgery in cerebral hemorrhage.
Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to evaluate the efficacy and safety of laser localization combined with soft-channel minimally invasive surgery (MIS) for the treatment of cerebral hemorrhage, and to develop stereotactic alternatives that are cost-effective, safe and precise for underdeveloped regions. To meet this aim, 60 patients with cerebral hemorrhage were randomly assigned to the control group (n=30) or the study group (n=30). The patients in the study group were treated with laser localization combined with soft-channel MIS to remove the hematoma, whereas the control group was treated with YL-1 needle puncture to drain the intracranial hemorrhage. All patients underwent successful surgical treatment. The hematoma clearance rate was revealed to be 88.72±2.82% in the study group and 84.50±4.26% in the control group. Both groups achieved residual hematoma volume <10 ml or a hematoma clearance rate >70%, and the difference in the hematoma clearance rate was found to be statistically significant (P<0.05), with the study group having an improved hematoma clearanc2e rate compared with the control group. The median 7-day postoperative Glasgow Coma Scale score was 13.0 [interquartile range (IQR), 12.0, 14.0] for the study group and 12.0 (IQR, 11.0, 13.0) for the control group, indicating an improved outcome in the study group. The puncture accuracy was 100% (30/30) in the study group compared with 76.66% (23/30) in the control group (P<0.05). The hematoma drainage time was found to be significantly shorter in the study group (40.57±8.24 h) compared with that in the control group (56.80±14.40 h) (P<0.05). At the 6-month follow-up, the median modified Rankin Scale score was found to be 2.0 (IQR, 2.0, 3.0) in both groups. Neither group experienced rebleeding, hydrocephalus or cerebral infarction. No intracranial infections occurred in the treatment group, whereas three cases of intracranial infection were observed in the control group. In conclusion, the findings of the present study have shown that laser localization combined with soft-channel MIS is effective and safe in the treatment of cerebral hemorrhage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.